Apellis Pharmaceuticals, Inc.
APLS
Revenue
199.69M
▲27.36M▲15.88%
3 Months ChangeAssets
904.48M
▲72.55M▲8.72%
3 Months ChangeLiabilities
640.16M
▲74.90M▲13.25%
3 Months ChangeFree Cash Flow
-133.28M
▲44.60M▲25.07%
12 Months ChangeRevenue/Cost Of Revenue
Revenue
Cost Of Revenue
Loading...
| Date | Revenue | Cost Of Revenue |
|---|---|---|
Net Profit/Loss
Net Profit/Loss
Baseline
Loading...
| Date | Net Profit/Loss |
|---|---|
Assets/Liabilities
Assets
Liabilities
Loading...
| Date | Assets | Liabilities |
|---|---|---|
Cash Flows
Operating (Cash Flow)
Investing (Cash Flow)
Financing (Cash Flow)
Free Cash Flow
Loading...
| Date | Operating (Cash Flow) | Investing (Cash Flow) | Financing (Cash Flow) | Free Cash Flow |
|---|---|---|---|---|
EPS
EPS (Diluted)
Loading...
| Date | EPS | EPS (Diluted) |
|---|---|---|
Outstanding Shares
Loading...
| Date | Outstanding Shares |
|---|---|
Recent 8-K/10-Q Filings
2024-08-08
Form 8-K
ID: 0001193125-24-196465
2024-08-01
Form 10-Q
ID: 0000950170-24-088938
2024-06-05
Form 8-K
ID: 0001193125-24-155179
2024-05-14
Form 8-K
ID: 0001193125-24-137743
2024-05-07
Form 10-Q
ID: 0000950170-24-053921
2024-02-27
Form 8-K
ID: 0001193125-24-047073
2024-01-22
Form 8-K
ID: 0001193125-24-011699
2024-01-08
Form 8-K
ID: 0001193125-24-003998
2023-12-14
Form 8-K
ID: 0001193125-23-294892
2023-12-01
Form 8-K
ID: 0001193125-23-286826